Membranous CD44v6 is upregulated as an early event in colorectal cancer: Downregulation is associated with circulating tumor cells and poor prognosis

Kataki,Agapi; Giannakoulis,Vassilis G.; Derventzi,Anastasia; Papiris,Konstantinos; Koniaris,Eythimios; Konstadoulakis,Manousos

doi:10.3892/ol.2021.13081

Membranous CD44v6 is upregulated as an early event in colorectal cancer: Downregulation is associated with circulating tumor cells and poor prognosis

Authors:
- Agapi Kataki
- Vassilis G. Giannakoulis
- Anastasia Derventzi
- Konstantinos Papiris
- Eythimios Koniaris
- Manousos Konstadoulakis
View Affiliations

Affiliations: First Department of Propaedeutic Surgery, Hippokration General Hospital of Athens, Athens 11527, Greece, Department of Endoscopy, Hippokration General Hospital of Athens, Athens 11527, Greece, Department of Pathology, Hippokration General Hospital of Athens, Athens 11527, Greece, Second Surgery Clinic, Aretaieio Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens 11528, Greece
Published online on: October 8, 2021 https://doi.org/10.3892/ol.2021.13081
Article Number: 820
Copyright: © Kataki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that CD44 variant 6 (CD44v6) and metastasis‑associated protein 1 (MTA1) are contributing factors to cancer progression. The present study aimed to evaluate the expression profiles for associations with patients' demographic data, clinicopathological characteristics, the presence of partial epithelial‑to‑mesenchymal transition (pEMT), metastatic potential based on the presence of CK20⁺ CEA⁺ CXCR4⁺ circulating tumor cells (CTCs) and prognosis (median follow‑up, 45 months). Thus, frozen tissue samples from 31 patients with stage I‑III colorectal cancer (CRC), 15 benign colorectal polyps and seven normal colorectal tissues were analyzed to detect membranous (m)CD44v6 and MTA1 expression via flow cytometry. The results demonstrated that the mCD44v6 and MTA1 expression profiles were significantly correlated (r_s=+0.786, P<0.001). Notably, MTA1 expression was not associated with any of the clinicopathological characteristics assessed. The percentage of mCD44v6‑positive cells within tumors was higher in the right‑sided cancer lesions (P=0.014), suggesting that proximal and distal CRCs are distinct clinicopathological entities. Furthermore, downregulated mCD44v6 expression was significantly associated with the presence of CTCs (P=0.017). This association was stronger for pEMT (co‑expression of N‑ and E‑cadherin mRNAs) primary lesions (P=0.009). In addition, patients with CRC with low levels of mCD44v6 had unfavorable survival outcomes (P=0.037). Taken together, these results suggest that targeted analysis of membranous CD44v6 as opposed to membranous‑cytoplasmic expression is important in determining the prognosis of patients with CRC. Furthermore, downregulated mCD44v6 expression in malignancies presenting CTCs reinforces the importance of tumor‑stroma reciprocal influence during the metastatic process and encourages the assessment of relevant therapeutic strategies.

View Figures

View References

1	Rawla P, Sunkara T and Barsouk A: Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol. 14:89–103. 2019.PubMed/NCBI
2	De Palma FDE, D'argenio V, Pol J, Kroemer G, Maiuri MC and Salvatore F: The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel). 11:10172019. View Article : Google Scholar : PubMed/NCBI
3	Okabe H, Mima K, Saito S, Hayashi H, Imai K, Nitta H, Hashimoto D, Chikamoto A, Ishiko T, Beppu T and Baba H: Epithelial-mesenchymal transition in gastroenterological cancer. J Cancer Metastasis Treat. 1:183–189. 2015. View Article : Google Scholar
4	Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells. 8:11182019. View Article : Google Scholar : PubMed/NCBI
5	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN and Levine H: Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 5:1552015. View Article : Google Scholar : PubMed/NCBI
7	Aiello NM and Kang Y: Context-dependent EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019. View Article : Google Scholar : PubMed/NCBI
8	Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y and Baba H: CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep. 29:1570–1578. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tuncay Cagatay S, Cimen I, Savas B and Banerjee S: MTA-1 expression is associated with metastasis and epithelial to mesenchymal transition in colorectal cancer cells. Tumor Biol. 34:1189–1204. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang Z, Zhao K, Hackert T and Zöller M: CD44/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression. Front Cell Dev Biol. 6:972018. View Article : Google Scholar : PubMed/NCBI
11	Chen C, Zhao S, Karnad A and Freeman JW: The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol. 11:642018. View Article : Google Scholar : PubMed/NCBI
12	McAtee CO, Barycki JJ and Simpson MA: Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv Cancer Res. 123:1–34. 2014. View Article : Google Scholar : PubMed/NCBI
13	Misra S, Hascall VC, Markwald RR and Ghatak S: Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol. 6:2012015. View Article : Google Scholar : PubMed/NCBI
14	Liu J, Xu D, Wang H, Zhang Y, Chang Y, Zhang J, Wang J, Li C, Liu H, Zhao M, et al: The subcellular distribution and function of MTA1 in cancer differentiation. Oncotarget. 5:5153–5164. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lozar T, Gersak K, Cemazar M, Kuhar CG and Jesenko T: The biology and clinical potential of circulating tumor cells. Radiol Oncol. 53:131–147. 2019. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Zhou Y and Hu Z: The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement. J Transl Intern Med. 5:135–138. 2017. View Article : Google Scholar : PubMed/NCBI
17	Welinder C, Jansson B, Lindell G and Wenner J: Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. Cancer Lett. 358:43–46. 2015. View Article : Google Scholar : PubMed/NCBI
18	Lagoudianakis EE, Kataki A, Manouras A, Memos N, Papadima A, Derventzi A, Zografos G, Papadopoulos S, Katergiannakis V and Konstadoulakis MM: Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res. 155:183–190. 2007. View Article : Google Scholar : PubMed/NCBI
19	Miller RJ, Banisadr G and Bhattacharyya BJ: CXCR4 signaling in the regulation of stem cell migration and development. J Neuroimmunol. 198:31–38. 2008. View Article : Google Scholar : PubMed/NCBI
20	Riihimäki M, Hemminki A, Sundquist J and Hemminki K: Patterns of metastasis in colon and rectal cancer. Sci Rep. 6:297652016. View Article : Google Scholar : PubMed/NCBI
21	Liepelt A and Tacke F: Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. Am J Physiol Gastrointest Liver Physiol. 311:G203–G209. 2016. View Article : Google Scholar : PubMed/NCBI
22	Werb Z and Lu P: The role of Stroma in tumor development. Cancer J. 21:250–253. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Liu Q, Lin D and Lai M: CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma. Int J Clin Exp Pathol. 8:14283–14293. 2015.PubMed/NCBI
24	Afify A, Durbin-Johnson B, Virdi A and Jess H: The expression of CD44v6 in colon: From normal to malignant. Ann Diagn Pathol. 20:19–23. 2016. View Article : Google Scholar : PubMed/NCBI
25	Kim H, Yang XL, Rosada C, Hamilton SR and August JT: CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys. 310:504–507. 1994. View Article : Google Scholar : PubMed/NCBI
26	Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, et al: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhao LH, Lin QL, Wei J, Huai YL, Wang KJ and Yan HY: CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol. 8:692–701. 2015.PubMed/NCBI
28	Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet J, Cooper DL, Nicosia SV and Cooper HS: CD44V6 expression in human colorectal carcinoma. Hum Pathol. 29:627–635. 1998. View Article : Google Scholar : PubMed/NCBI
29	Zlobec I, Günthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L and Lugli A: Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology. 55:564–575. 2009. View Article : Google Scholar : PubMed/NCBI
30	Wang JL, Su WY, Lin YW, Xiong H, Chen YX, Xu J and Fang JY: CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis. Oncotarget. 8:12866–12876. 2017. View Article : Google Scholar : PubMed/NCBI
31	Okabe H, Ishimoto T, Mima K, Nakagawa S, Hayashi H, Kuroki H, Imai K, Nitta H, Saito S, Hashimoto D, et al: CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br J Cancer. 110:958–966. 2014. View Article : Google Scholar : PubMed/NCBI
32	Minoo P, Zlobec I, Peterson M, Terracciano L and Lugli A: Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 37:707–718. 2010. View Article : Google Scholar : PubMed/NCBI
33	Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T and Güller U: Better survival in right-sided versus left-sided stage I–III colon cancer patients. BMC Cancer. 16:5542016. View Article : Google Scholar : PubMed/NCBI
34	Aramaki Y, Ogawa K, Toh Y, Ito T, Akimitsu N, Hamamoto H, Sekimizu K, Matsusue K, Kono A, Iguchi H and Takiguchi S: Direct interaction between metastasis-associated protein 1 and endophilin 3. FEBS Lett. 579:3731–3736. 2005. View Article : Google Scholar : PubMed/NCBI
35	Cao G, Chen B and Xiong M: Role of metastasis-associated protein 1 in prognosis of patients with digestive tract cancers: A meta-analysis. PLoS One. 12:e01764312017. View Article : Google Scholar : PubMed/NCBI
36	Karamagkiolas S, Giotakis I, Kyrodimos E, Giotakis EI, Kataki A, Karagianni F and Lazaris AM: Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients. Am J Otolaryngol. 40:487–493. 2019. View Article : Google Scholar : PubMed/NCBI
37	Chen XL, Wu YJ, Lv Z, Zhao HM and Han BJ: Significance of expression of MTA1 and RECK in carcinogenesis of colonic polyps. World Chinese J Dig. 24:4514–4518. 2016. View Article : Google Scholar
38	Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, et al: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 141:2076–2087.e6. 2011. View Article : Google Scholar : PubMed/NCBI